Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded access program for Tradipitant

Next Previous
X
Search
Trial Profile

Expanded access program for Tradipitant

Status: Not stated
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Gastroparesis
  • Focus Expanded access; Therapeutic Use

    • Most Recent Events

    • 31 Jan 2025 New trial record
    • 27 Jan 2025 According to a Vanda Pharmaceuticals media release, The FDA also discounted the evidence from patients in the expanded access program, some treated for more than a year, who showed large improvement while on treatment. Vanda disagreed and requested copies of the FDA reviews under Freedom of Information Act (FOIA). The FDA published those conclusions in the Federal Register, and gave a Notice of Opportunity for Hearing (NOOH) to Vanda, which the company has accepted.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top